FMS vs. RPRX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at FMS and RPRX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
FMS trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, RPRX is a standard domestic listing.
| Symbol | FMS | RPRX |
|---|---|---|
| Company Name | Fresenius Medical Care AG | Royalty Pharma plc |
| Country | Germany | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Pharmaceuticals |
| Market Capitalization | 14.58 billion USD | 21.26 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | September 17, 1996 | June 16, 2020 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of FMS and RPRX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | FMS | RPRX |
|---|---|---|
| 5-Day Price Return | 2.02% | -1.49% |
| 13-Week Price Return | -17.32% | 9.33% |
| 26-Week Price Return | -11.70% | 16.11% |
| 52-Week Price Return | 20.91% | 37.90% |
| Month-to-Date Return | -7.06% | -0.92% |
| Year-to-Date Return | -6.39% | 42.92% |
| 10-Day Avg. Volume | 0.64M | 3.38M |
| 3-Month Avg. Volume | 0.56M | 4.31M |
| 3-Month Volatility | 22.56% | 22.10% |
| Beta | 0.60 | 0.59 |
Profitability
Return on Equity (TTM)
FMS
4.70%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
FMS’s Return on Equity of 4.70% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
RPRX
15.20%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
RPRX’s Return on Equity of 15.20% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
FMS
3.36%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
FMS’s Net Profit Margin of 3.36% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
RPRX
44.28%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
RPRX’s Net Profit Margin of 44.28% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
FMS
7.57%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
FMS’s Operating Profit Margin of 7.57% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
RPRX
79.84%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
RPRX’s Operating Profit Margin of 79.84% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | FMS | RPRX |
|---|---|---|
| Return on Equity (TTM) | 4.70% | 15.20% |
| Return on Assets (TTM) | 2.02% | 5.66% |
| Net Profit Margin (TTM) | 3.36% | 44.28% |
| Operating Profit Margin (TTM) | 7.57% | 79.84% |
| Gross Profit Margin (TTM) | 24.67% | -- |
Financial Strength
Current Ratio (MRQ)
FMS
1.44
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
FMS’s Current Ratio of 1.44 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
RPRX
1.26
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
RPRX’s Current Ratio of 1.26 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
FMS
0.83
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
FMS’s Debt-to-Equity Ratio of 0.83 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RPRX
1.26
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
RPRX’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.26. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
FMS
5.73
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
FMS’s Interest Coverage Ratio of 5.73 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
RPRX
4.70
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
RPRX’s Interest Coverage Ratio of 4.70 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | FMS | RPRX |
|---|---|---|
| Current Ratio (MRQ) | 1.44 | 1.26 |
| Quick Ratio (MRQ) | 1.08 | 1.26 |
| Debt-to-Equity Ratio (MRQ) | 0.83 | 1.26 |
| Interest Coverage Ratio (TTM) | 5.73 | 4.70 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
FMS
3.48%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 3.48%, FMS offers a more attractive income stream than most of its peers in the Health Care Providers & Services industry, signaling a strong commitment to shareholder returns.
RPRX
1.81%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
RPRX’s Dividend Yield of 1.81% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
FMS
187.56%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
At 187.56%, FMS’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Health Care Providers & Services industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
RPRX
36.87%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
RPRX’s Dividend Payout Ratio of 36.87% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | FMS | RPRX |
|---|---|---|
| Dividend Yield (TTM) | 3.48% | 1.81% |
| Dividend Payout Ratio (TTM) | 187.56% | 36.87% |
Valuation
Price-to-Earnings Ratio (TTM)
FMS
18.48
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
FMS’s P/E Ratio of 18.48 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
RPRX
20.35
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
RPRX’s P/E Ratio of 20.35 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
FMS
0.62
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
FMS’s P/S Ratio of 0.62 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RPRX
9.01
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
With a P/S Ratio of 9.01, RPRX trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
FMS
1.07
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
FMS’s P/B Ratio of 1.07 is in the lower quartile for the Health Care Providers & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
RPRX
3.19
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
RPRX’s P/B Ratio of 3.19 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | FMS | RPRX |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 18.48 | 20.35 |
| Price-to-Sales Ratio (TTM) | 0.62 | 9.01 |
| Price-to-Book Ratio (MRQ) | 1.07 | 3.19 |
| Price-to-Free Cash Flow Ratio (TTM) | 6.02 | 17.25 |